MAP3K5 and craniodiaphyseal dysplasia: Previous studies have indicated that CDD can enhance PKP3 promoter methylation to reduce PKP3 expression (18), downregulate FOXK1 (42), inhibit the Wnt/β-Catenin signaling pathway (17), inhibit the ASK1/JNK pathway (43), inhibit granulosa cell apoptosis, and play a restorative role in ovarian morphology.